159 related articles for article (PubMed ID: 11061551)
1. Quantitative determination of sst2 gene expression in neuroblastoma tumor predicts patient outcome.
Raggi CC; Maggi M; Renzi D; Calabrò A; Bagnoni ML; Scaruffi P; Tonini GP; Pazzagli M; De Bernardi B; Bernini G; Serio M; Orlando C
J Clin Endocrinol Metab; 2000 Oct; 85(10):3866-73. PubMed ID: 11061551
[TBL] [Abstract][Full Text] [Related]
2. Somatostatin receptor type 2 gene expression in neuroblastoma, measured by competitive RT-PCR, is related to patient survival and to somatostatin receptor imaging by indium -111-pentetreotide.
Orlando C; Raggi CC; Bagnoni L; Sestini R; Briganti V; La Cava G; Bernini G; Tonini GP; Pazzagli M; Serio M; Maggi M
Med Pediatr Oncol; 2001 Jan; 36(1):224-6. PubMed ID: 11464890
[TBL] [Abstract][Full Text] [Related]
3. Quantitation of somatostatin receptor type 2 gene expression in neuroblastoma cell lines and primary tumors using competitive reverse transcription-polymerase chain reaction.
Sestini R; Orlando C; Peri A; Tricarico C; Pazzagli M; Serio M; Pagani A; Bussolati G; Granchi S; Maggi M
Clin Cancer Res; 1996 Oct; 2(10):1757-65. PubMed ID: 9816127
[TBL] [Abstract][Full Text] [Related]
4. Imaging of somatostatin receptors by indium-111-pentetreotide correlates with quantitative determination of somatostatin receptor type 2 gene expression in neuroblastoma tumors.
Briganti V; Sestini R; Orlando C; Bernini G; La Cava G; Tamburini A; Raggi CC; Serio M; Maggi M
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2385-91. PubMed ID: 9815638
[TBL] [Abstract][Full Text] [Related]
5. Expression of B-myb in neuroblastoma tumors is a poor prognostic factor independent from MYCN amplification.
Raschellà G; Cesi V; Amendola R; Negroni A; Tanno B; Altavista P; Tonini GP; De Bernardi B; Calabretta B
Cancer Res; 1999 Jul; 59(14):3365-8. PubMed ID: 10416595
[TBL] [Abstract][Full Text] [Related]
6. MYCN RNA levels determined by quantitative in situ hybridization is better than MYCN gene dosages in predicting the prognosis of neuroblastoma patients.
Chang HH; Tseng YF; Lu MY; Yang YL; Chou SW; Lin DT; Lin KH; Jou ST; Hsu WM; Jeng YM
Mod Pathol; 2020 Apr; 33(4):531-540. PubMed ID: 31695155
[TBL] [Abstract][Full Text] [Related]
7. Relationship of DDX1 and NAG gene amplification/overexpression to the prognosis of patients with MYCN-amplified neuroblastoma.
Kaneko S; Ohira M; Nakamura Y; Isogai E; Nakagawara A; Kaneko M
J Cancer Res Clin Oncol; 2007 Mar; 133(3):185-92. PubMed ID: 17028906
[TBL] [Abstract][Full Text] [Related]
8. Type-2 somatostatin receptor mRNA levels in breast and colon cancer determined by a quantitative RT-PCR assay based on dual label fluorogenic probe and the TaqMan technology.
Pinzani P; Orlando C; Raggi CC; Distante V; Valanzano R; Tricarico C; Maggi M; Serio M; Pazzagli M
Regul Pept; 2001 Jun; 99(2-3):79-86. PubMed ID: 11384768
[TBL] [Abstract][Full Text] [Related]
9. MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN.
Cohn SL; London WB; Huang D; Katzenstein HM; Salwen HR; Reinhart T; Madafiglio J; Marshall GM; Norris MD; Haber M
J Clin Oncol; 2000 Nov; 18(21):3604-13. PubMed ID: 11054433
[TBL] [Abstract][Full Text] [Related]
10. MYCN protein expression as a predictor of neuroblastoma prognosis.
Chan HS; Gallie BL; DeBoer G; Haddad G; Ikegaki N; Dimitroulakos J; Yeger H; Ling V
Clin Cancer Res; 1997 Oct; 3(10):1699-706. PubMed ID: 9815553
[TBL] [Abstract][Full Text] [Related]
11. TrkA expression in peripheral neuroblastic tumors: prognostic significance and biological relevance.
Shimada H; Nakagawa A; Peters J; Wang H; Wakamatsu PK; Lukens JN; Matthay KK; Siegel SE; Seeger RC
Cancer; 2004 Oct; 101(8):1873-81. PubMed ID: 15386308
[TBL] [Abstract][Full Text] [Related]
12. Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification.
Krams M; Hero B; Berthold F; Parwaresch R; Harms D; Rudolph P
Cancer; 2002 Feb; 94(3):854-61. PubMed ID: 11857322
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of MYCN, DDX1, TrkA, and TrkC gene transcripts expression in neuroblastoma.
de Souza DR; Sanabani SS; de Souza AC; Filho Odone V; Epelman S; Bendit I
Pediatr Blood Cancer; 2011 May; 56(5):749-56. PubMed ID: 21154590
[TBL] [Abstract][Full Text] [Related]
14. Full-length telomerase reverse transcriptase messenger RNA is an independent prognostic factor in neuroblastoma.
Krams M; Hero B; Berthold F; Parwaresch R; Harms D; Rudolph P
Am J Pathol; 2003 Mar; 162(3):1019-26. PubMed ID: 12598334
[TBL] [Abstract][Full Text] [Related]
15. Cross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes.
Warnat P; Oberthuer A; Fischer M; Westermann F; Eils R; Brors B
BMC Cancer; 2007 May; 7():89. PubMed ID: 17531100
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of MYCN and ID2 overexpression in neuroblastoma.
Alaminos M; Gerald WL; Cheung NK
Pediatr Blood Cancer; 2005 Dec; 45(7):909-15. PubMed ID: 16047351
[TBL] [Abstract][Full Text] [Related]
17. Pilot study to evaluate MYCN expression as a neuroblastoma cell marker to detect minimal residual disease by RT-PCR.
Wagner LM; Burger RA; Guichard SM; Raimondi SC; Santana VM; Furman WL; Barnette P; Danks MK
J Pediatr Hematol Oncol; 2006 Oct; 28(10):635-41. PubMed ID: 17023822
[TBL] [Abstract][Full Text] [Related]
18. Influence of 17q gain and promoter polymorphisms on mRNA expression of somatostatin receptor type 2 in neuroblastoma.
Simi L; Pinzani P; Raggi CC; Pazzagli M; Orlando C
Clin Chim Acta; 2007 Sep; 384(1-2):149-54. PubMed ID: 17678886
[TBL] [Abstract][Full Text] [Related]
19. Expression of KIT and PDGFR is associated with a good prognosis in neuroblastoma.
Shimada A; Hirato J; Kuroiwa M; Kikuchi A; Hanada R; Wakai K; Hayashi Y
Pediatr Blood Cancer; 2008 Feb; 50(2):213-7. PubMed ID: 17941064
[TBL] [Abstract][Full Text] [Related]
20. Co-expression analysis identifies long noncoding RNA SNHG1 as a novel predictor for event-free survival in neuroblastoma.
Sahu D; Hsu CL; Lin CC; Yang TW; Hsu WM; Ho SY; Juan HF; Huang HC
Oncotarget; 2016 Sep; 7(36):58022-58037. PubMed ID: 27517149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
